CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenue:
Total revenue	$ 2,137	$ 10,000	$ 2,137	$ 10,000
Operating expenses:
Cost of sales - product	318		318
Cost of sales - intangible amortization	128		128
Research and development	24,786	18,062	53,938	35,769
Selling, general and administrative	20,669	10,215	35,692	20,567
Total operating expenses	45,901	28,277	90,076	56,336
Loss from operations	(43,764)	(18,277)	(87,939)	(46,336)
Other expense	(110)	(24)	(149)	(54)
Interest income	822	983	1,782	2,350
Interest expense	(212)	(1,138)	(404)	(2,268)
Loss on debt extinguishment			(1,826)
Change in fair value of preferred stock tranche liability		10,200		4,189
Change in fair value of warrant liability	20,320		17,904
Change in fair value of Notes	(2,990)		(7,405)
Net loss	$ (25,934)	$ (8,256)	$ (78,037)	$ (42,119)
Net loss per share-basic	$ (0.39)	$ (0.31)	$ (1.3)	$ (1.57)
Net loss per share-diluted	$ (0.62)	$ (0.31)	$ (1.41)	$ (1.57)
Weighted average common shares outstanding used in computing net loss per share - basic	66,143	26,861	60,191	26,846
Weighted average common shares outstanding used in computing net loss per share - diluted	74,037	26,861	68,182	26,846
Net loss	$ (25,934)	$ (8,256)	$ (78,037)	$ (42,119)
Unrealized gain (loss) on available-for-sale securities		4		(13)
Change in fair value of Notes attributable to instrument specific credit risk	1,349		(5,290)
Comprehensive loss	(24,585)	(8,252)	(83,327)	(42,132)
Product revenue, net
Revenue:
Revenue	$ 2,137		$ 2,137
Sale of COPIKTRA license and related assets
Revenue:
Revenue		$ 10,000		$ 10,000